Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
Part of paid clinical trials in Lincoln, Nebraska.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07629999
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Healthy Volunteers
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- BMS-986533 — DRUGSpecified dose on specified days
- Famotidine — DRUGSpecified dose on specified days
- Placebo — DRUGSpecified dose on specified days
- Dabigatran Etexilate — DRUGSpecified dose on specified days
- Rosuvastatin — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the safety and pharmacokinetics of BMS-986533 in healthy participants receiving single and multiple doses, to assess food and pH effects on the relative bioavailability of BMS-986533, and the P-gp and BCRP-mediated drug-drug interaction potential of the study drug
Key Dates
- First listed
- Jun 5, 2026
- Start date
- Jul 13, 2026
- Status verified
- Jul 2026
- Primary completion
- Jun 1, 2027
- Completion
- Jun 1, 2027
Study Design
- Enrollment
- 136 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A
- Experimental: Arm B
- Experimental: Arm C
- Experimental: Arm D
Primary Outcome Measure
Number of participants with Adverse Events (AE) [ Time Frame: Up to Day 47 ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Celerion Coorporate Office Nebraska | Lincoln | Nebraska | 68502 | Allen Hunt, Site 0001 |
Find similar trials in Lincoln, NE
By research site
Related Studies
- Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderPHASE1/PHASE2 · Recruiting · Sanofi · Gadsden, Alabama
- Evaluation of Patients With Mood and Anxiety Disorders and Healthy VolunteersRecruiting · National Institute of Mental Health (NIMH) · Bethesda, Maryland
- Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family MembersEnrolling By Invitation · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Cytapheresis of Volunteer DonorsRecruiting · National Institute on Aging (NIA) · Baltimore, Maryland